|
Bipolar Disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Several genes within this GAD1 regulatory network show diagnosis- and sector-specific expression changes within the circuitry of the hippocampus, influencing abnormal GAD1 expression in schizophrenia and bipolar disorder.
|
25738424 |
2015 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
The DNMT1 increase and the GAD67 decrease in BA9 interneurons are significant features of SZ and bipolar disorder with psychosis.
|
15684088 |
2005 |
|
Bipolar Disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This is the first demonstration that there is more DNA fragmentation in cells showing no detectable GAD67 mRNA in patients with bipolar disorder than in schizophrenics or controls.
|
17442540 |
2007 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
The copy number intensities examined using both microarrays and quantitative real-time polymerase chain reaction for the GAD67 gene were significantly decreased in sector CA3/2 of patients with schizophrenia and patients with bipolar disorder.
|
22309971 |
2012 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
In schizophrenia and bipolar disorder, a network of genes involved in the regulation of GAD₆₇, a marker for the functional differentiation of GABA cells, show pronounced changes in expression and include kainate receptor subunits, TGFβ and Wnt signaling pathways, epigenetic factors and transcription factors.
|
21184762 |
2011 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
We found that the density of GAD67+ neurons in layers 2-5 of the prefrontal cortex was decreased by 27-36% in both schizophrenia and bipolar disorder.
|
18534564 |
2008 |
|
Bipolar Disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Previous studies suggest linkage between D2S326 near GAD1 and BPAD.
|
15806582 |
2005 |
|
Bipolar Disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Lastly, we examined the associations of the GAD1 gene and BD in two additional independent datasets with a few thousand samples for replication.
|
28710909 |
2017 |
|
Bipolar Disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
A research strategy directed toward identifying specific neurochemical markers operative in the etiopathology of psychotic disorders lead to the identification of a downregulation (30-50%) of Reln and glutamic acid decarboxylase 67(GAD67) expression in prefrontal cortex and other brain areas of schizoprenia and bipolar disorder patients with psychosis.
|
11059795 |
2000 |
|
Bipolar Disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Schizophrenia (SZ) and bipolar disorder (BPD) patients show a downregulation of GAD67, reelin (RELN), brain-derived neurotrophic factor (BDNF), and other genes expressed in telencephalic GABAergic and glutamatergic neurons.
|
25364290 |
2014 |
|
Major Depressive Disorder
|
0.530 |
Biomarker
|
disease |
BEFREE |
We used real-time quantitative polymerase chain reaction (qPCR) to assess expression levels of two GABA synthesizing enzymes (glutamate decarboxylase; GAD65 and GAD67) and of three markers of GABA neuron subpopulations (PV, CR, SST) in the dorsolateral prefrontal cortex (DLPFC; Brodmann area 9) in triads (n=19) of control subjects and matched subjects with BPD or MDD.
|
21226980 |
2011 |
|
Major Depressive Disorder
|
0.530 |
AlteredExpression
|
disease |
BEFREE |
This exploratory study provides an initial step for future studies to investigate an association between the reductions in SLC1A2 and GAD1 mRNA expression and their relation to the attenuation of the RAF/MEK/ERK signaling pathway in the dlPFC in MDD.
|
24652383 |
2014 |
|
Major Depressive Disorder
|
0.530 |
GeneticVariation
|
disease |
BEFREE |
Subject to confirmation in an independent sample, our study suggests that variations in the GAD1 gene may contribute to individual differences in N and impact susceptibility across a range of anxiety disorders and major depression.
|
16718280 |
2006 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Primary outcome measures were assessed with the Generalized Anxiety Disorder Scale (GAD-7), Personal Health Questionnaire Depression Scale (PHQ-8), Perceived Stress Scale (PSS-14), and Pittsburgh Sleep Symptom Questionnaire-Insomnia (PSSQ-1).
|
29351138 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
They completed the Centre for Epidemiologic Studies Depression Scale (CES-D) and the General Anxiety Disorder Scale (GAD-7) to measure whether they experience depression and/or anxiety symptoms.
|
29543833 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Respectively 21.4% and 7.8% of the participants had depression and clinical symptoms of GAD.
|
30550597 |
2018 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A binary logistic regression analyses were conducted to test the association between all four ratings in GAD-7 (anxiety) and PHQ-9 (depression) scales subitems as covariates, and migraine vs no headache as the outcome.
|
28324317 |
2017 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Changes in DEMS correlated with changes in both PHQ-8 and GAD-7 in the subgroup of patients without prior depression or anxiety diagnosis (ρ = 0.6, P = 0.002; ρ = 0.4, P = 0.02).
|
30950896 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Depression was more commonly studied (ranged from 1%-30%).Prevalence of GAD ranged from 1%-26%.
|
29966886 |
2018 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
Of the 336 usable responses, 16.1% scored 10 or greater on the PHQ-8 consistent with current depression while 17.3% scored 10 or greater on the GAD-7 consistent with current anxiety.
|
30637564 |
2019 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Participants were 307 psychiatry outpatients with depression; assessed at baseline, 3-, and 6-months on symptom (PHQ-9 and GAD-7), functioning (SF-12) and past-month marijuana use for a substance use intervention trial.
|
28242498 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The resulting groups were characterized with regard to Quality of Life (MacNew), anxiety and depression (GAD-7 and PHQ-9) and resilience (RS-13).
|
28006984 |
2017 |
|
Mental Depression
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a cross-sectional study, 23 patients with IPF were evaluated using Montreal Cognitive Assessment (MoCA), an instrument for detecting mild cognitive impairments and were screened for OSA through overnight cardiorespiratory polygraphy and for anxiety and depression with three specific scale (Generalized Anxiety Disorder 7-item scale: GAD-7; the Patient Health Questionnaire: PHQ-9; Hospital Anxiety and Depression Scale: HADS).
|
30707735 |
2019 |
|
Mental Depression
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Self-report questionnaires were administered to assess quality of life (12-item Kansas City Cardiomyopathy Questionnaire quality of life subscale), level of anxiety (7-item Generalized Anxiety Disorder; GAD-7), level of depression (9-item Patient Health Questionnaire; PHQ-9) and device acceptance (Florida Patient Acceptance Survey; FPAS) to 101 consecutive patients presenting to LVAD clinic.
|
31346241 |
2019 |
|
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
The PHQ-9 and GAD-7 were determined to be potential screening tools to aid Chinese medical workers in recognizing depression and anxiety in nonpsychiatric departments.
|
30762438 |
2019 |